During the recent session, Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s traded shares were 1.14 million, with the beta value of the company hitting 2.83. At the last check today, the stock’s price was $1.60, reflecting an intraday gain of 0.63% or $0.01. The 52-week high for the BDTX share is $7.66, that puts it down -378.75 from that peak though still a striking 1.88% gain since the share price plummeted to a 52-week low of $1.57. The company’s market capitalization is $90.66M, and the average intraday trading volume over the past 10 days was 15.63 million shares, and the average trade volume was 3.30 million shares over the past three months.
Black Diamond Therapeutics Inc (BDTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.14. BDTX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Black Diamond Therapeutics Inc (NASDAQ:BDTX) trade information
Black Diamond Therapeutics Inc (BDTX) registered a 0.63% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.63% in intraday trading to $1.60, hitting a weekly high. The stock’s 5-day price performance is -14.89%, and it has moved by -21.95% in 30 days. Based on these gigs, the overall price performance for the year is -69.17%. The short interest in Black Diamond Therapeutics Inc (NASDAQ:BDTX) is 7.16 million shares and it means that shorts have 16.18 day(s) to cover.
The consensus price target of analysts on Wall Street is $14, which implies an increase of 88.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $11 and $20 respectively. As a result, BDTX is trading at a discount of -1150.0% off the target high and -587.5% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -5.22%. While earnings are projected to return 43.16% in 2025, the next five years will return -6.71% per annum.
BDTX Dividends
Black Diamond Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s Major holders
Black Diamond Therapeutics Inc insiders own 2.72% of total outstanding shares while institutional holders control 87.31%, with the float percentage being 89.75%. T. ROWE PRICE INVESTMENT MANAGEMENT, INC. is the largest shareholder of the company, while 123.0 institutions own stock in it. As of 2024-06-30, the company held over 10.66 million shares (or 20.5751% of all shares), a total value of $49.67 million in shares.
The next largest institutional holding, with 8.52 million shares, is of BELLEVUE GROUP AG’s that is approximately 16.4409% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $39.69 million.
Also, the Mutual Funds coming in first place with the largest holdings of Black Diamond Therapeutics Inc (BDTX) shares are T. Rowe Price Small-Cap Value Fund, Inc. and T. Rowe Price Small-Cap Stock Fund, Inc. Data provided on Dec 31, 2024 indicates that T. Rowe Price Small-Cap Value Fund, Inc. owns about 2.42 shares. This amounts to just over 4.28 percent of the company’s overall shares, with a $3.84 million market value. The same data shows that the other fund manager holds slightly less at 2.37, or about 4.19% of the stock, which is worth about $3.76 million.
